The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects

• Published in: British journal of clinical pharmacology Vol. 64; no. 3; pp. 292 - 303
• Main Authors: Stangier, Joachim, Rathgen, Karin, Stähle, Hildegard, Gansser, Dietmar, Roth, Willy
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.09.2007; Blackwell Science Inc
• Subjects: activated partial thromboplastin time; Administration, Oral; Adolescent; Adult; Anticoagulants - blood; Anticoagulants - pharmacokinetics; Anticoagulants - pharmacology; Area Under Curve; Benzimidazoles - blood; Benzimidazoles - pharmacokinetics; Benzimidazoles - pharmacology; Blood Coagulation Tests; Dabigatran; dabigatran etexilate; direct thrombin inhibitor; Dose-Response Relationship, Drug; Double-Blind Method; ecarin clotting time; Humans; Male; Middle Aged; pharmacodynamics; Pharmacokinetics & Pharmacodynamics; Pyridines - blood; Pyridines - pharmacokinetics; Pyridines - pharmacology

Aims The novel direct thrombin inhibitor (DTI), dabigatran etexilate (Boehringer Ingelheim Pharma GmbH & Co. KG), shows potential as an oral antithrombotic agent. Two double‐blind, randomized trials were undertaken to investigate the pharmacokinetics (PK), pharmacodynamics (PD) and tolerability...